Lifmior (etanercept biosimilar) / Pfizer - LARVOL DELTA

Long‐term safety and effectiveness of etanercept in pediatric psoriasis patients: Results from a prospective observational cohort study (ICPE 2020) - P=NA, N=72; In this one of the largest studies with the longest follow-up of pediatric psoriasis patients treated with etanercept in the real-world setting, no serious or opportunistic infections or malignancies were observed, and the majority of prospective patients had a decrease in disease severity after etanercept treatment."

Clinical data